Antihypertensive Therapy

Learning objectives

After completing this chapter, you should be able to recognize acute-onset severe hypertension; obtain a reliable pregnancy blood pressure; distinguish emergency treatment from chronic maintenance therapy; compare IV labetalol, IV hydralazine, and immediate-release oral nifedipine; prevent treatment delays; avoid abrupt hypotension; integrate fetal surveillance; and manage antihypertensive therapy during transport and postpartum care.

Opening transport scenario

A 27-year-old patient at 35 weeks’ gestation has persistent blood pressures of 172/114 and 168/112 mm Hg measured 15 minutes apart. She reports a severe headache and visual spots. Fetal heart-rate variability is minimal. The sending emergency department has no obstetric service, and the receiving maternal center is 50 minutes away. The team must treat the stroke-level maternal risk promptly without causing sudden hypotension or delaying transfer.

1. Recognizing the hypertensive emergency

Acute-onset severe hypertension in pregnancy or postpartum is generally defined as systolic blood pressure of at least 160 mm Hg, diastolic blood pressure of at least 110 mm Hg, or both, confirmed as persistent over approximately 15 minutes. Treatment should begin as soon as possible—ideally within 30–60 minutes of confirmed severe hypertension—to reduce maternal stroke and other end-organ injury.

Confirm the number without creating delay

• Use the correct cuff size on a supported arm at heart level.
• Repeat a severe value promptly; do not wait hours for routine vital-sign intervals.
• Assess headache, vision change, altered mental status, RUQ/epigastric pain, dyspnea, chest pain, oliguria, seizure, and fetal status.
• Activate the severe-hypertension pathway while confirming medication availability and IV access.
• Remember that severe hypertension may occur postpartum, including after discharge.

2. Treatment goals

The emergency goal is to lower blood pressure below the severe range and reduce the risk of intracranial hemorrhage, cardiac failure, placental abruption, and other organ injury. The goal is not an abrupt fall to “normal.” Excessive reduction can compromise cerebral, renal, and uteroplacental perfusion.

3. First-line emergency medications

IV labetalol, IV hydralazine, and immediate-release oral nifedipine are accepted first-line options. Choice depends on access, contraindications, prior doses, maternal heart rate, asthma or cardiac history, medication availability, and the ability to reassess.

4. Labetalol

Labetalol blocks alpha- and beta-adrenergic receptors, reducing vascular resistance without the same degree of reflex tachycardia seen with a pure vasodilator. It is fast and familiar but requires attention to maternal pulse, conduction, bronchospasm, and cardiac function.

• Verify that the patient has not already received oral or IV labetalol and calculate cumulative dose.
• Use a reliable IV line and confirm the dose in milligrams—not milliliters alone.
• Reassess BP and pulse at the protocol interval before redosing.
• Prepare an alternative if severe pressure persists at the cumulative maximum or contraindications develop.

5. Hydralazine

Hydralazine is a direct arterial vasodilator. Its onset and magnitude can be less predictable than labetalol, so the team must avoid stacking doses before the prior dose has taken effect. Maternal tachycardia, headache, and hypotension can complicate assessment because these symptoms may overlap with preeclampsia.

6. Immediate-release oral nifedipine

Immediate-release oral nifedipine is particularly useful when IV access is delayed or unavailable. It should be swallowed; sublingual use can cause unpredictable hypotension and is not recommended. Extended-release nifedipine is used for maintenance therapy, not as a direct substitute in an emergency algorithm.

7. Persistent severe hypertension

If severe blood pressure persists after the initial medication sequence, activate the next escalation step rather than repeating doses indefinitely. Confirm cuff accuracy, medication route, dose, and timing; consider pain, agitation, seizure, stimulant exposure, intracranial disease, pulmonary edema, and medication error. Contact obstetric leadership, anesthesia/critical care, and medical direction as appropriate.

8. Relationship to magnesium sulfate

Magnesium sulfate prevents or treats eclamptic seizures but does not reliably lower severe blood pressure. A patient may require magnesium and an antihypertensive simultaneously. Monitor respiratory status, reflexes, urine output, pulse, BP, and symptoms when therapies overlap.

9. Chronic and nonsevere hypertension

Emergency algorithms should not be confused with chronic-hypertension management. Current ACOG guidance based on the CHAP trial supports treatment of chronic hypertension using a threshold of 140/90 mm Hg. Common maintenance agents include labetalol and extended-release nifedipine; methyldopa is another option in selected cases. ACE inhibitors and angiotensin receptor blockers are generally avoided during pregnancy because of fetal risk, although postpartum medication choices differ.

10. Fetal and placental assessment

Maternal hypertension can reflect placental disease and may be associated with growth restriction, placental abruption, or fetal intolerance. During treatment, reassess fetal heart rate and uterine activity when feasible. Fetal deterioration should trigger maternal reassessment for hypotension, hypoxemia, abruption, tachysystole, or disease progression.

11. Transport implementation

• Treat confirmed severe hypertension before or during transfer according to capability; do not make transport the reason for delay.
• Document exact BP times, cuff location and size, confirmation time, medication time, dose, route, response, and adverse effects.
• Secure reliable IV access, airway equipment, magnesium and calcium plan when indicated, and continuous monitoring appropriate to acuity.
• Communicate the latest BP, symptoms, laboratory findings, fetal status, and remaining algorithm steps to the receiving team.
• Define diversion triggers: seizure, stroke signs, pulmonary edema, refractory severe BP, fetal bradycardia, abruption, or inability to support airway/hemodynamics.

12. Evolving case study

Phase 1: Recognition

BP remains 168/112 mm Hg after confirmation. Pulse is 92/min, lungs are clear, IV access is patent, and no labetalol contraindication is identified. The team activates the protocol while preparing magnesium for seizure prophylaxis.

Phase 2: Treatment

After IV labetalol 20 mg, BP remains severe at the protocol reassessment. The next ordered dose is administered. Symptoms and fetal status are reassessed; the team documents each time point and avoids compressing the interval.

Phase 3: Response

BP decreases to 148/94 mm Hg, headache improves, and fetal variability becomes moderate. The team continues transport with close reassessment rather than attempting to force BP into a low-normal range.

13. High-yield chapter summary

1. Persistent BP ≥160 systolic or ≥110 diastolic is an obstetric hypertensive emergency.
2. Confirm promptly and treat within 30–60 minutes—do not wait for proteinuria or laboratory results.
3. IV labetalol, IV hydralazine, and immediate-release oral nifedipine are first-line options.
4. Choose the agent using maternal pulse, asthma, heart block, cardiac function, access, and prior doses.
5. Use the correct reassessment interval; avoid dose stacking.
6. Magnesium prevents or treats seizures but is not the antihypertensive.
7. The goal is below the severe range, not abrupt normalization.
8. Treat postpartum severe hypertension with equal urgency.
9. Reassess maternal symptoms, fetal status, and possible placental abruption.
10. Document times, doses, response, adverse effects, and escalation clearly.

References

1. International Board of Specialty Certification. Maternal Fetal Transport Microcredential Candidate Handbook. Updated April 2026.
2. American College of Obstetricians and Gynecologists. Gestational Hypertension and Preeclampsia. Practice Bulletin No. 222. 2020.
3. American College of Obstetricians and Gynecologists. Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period.
4. ACOG District II Safe Motherhood Initiative. Severe Hypertension in Pregnancy Bundle: Labetalol, Hydralazine, and Oral Nifedipine Algorithms.
5. American College of Obstetricians and Gynecologists. Clinical Guidance for Integration of the Chronic Hypertension and Pregnancy Trial Findings. 2022.